Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 285 results
A petri dish with cell culture in a laboratory setting

May 11, 2026

Novo turns a Parkinson’s bet into a startup test

Novo Nordisk has transitioned its clinical-stage Parkinson's cell therapy, STEM-PD, to Cellular Intelligence, an AI-focused biotech supported by the Chan Zuckerberg Initiative. This strategic licensing deal illustrates a growing trend among pharmaceutical companies to offload non-core assets into specialized startups while maintaining a stake in their success through equity and potential royalties.By transferring STEM-PD, Novo Nordisk is not merely divesting a project but strategically managing
A glass flask with a colorful chemical compound in a dimly lit lab setting.

May 11, 2026

A year of advancing the Lilly-Purdue $250M research partnership to accelerate medicine discovery and manufacturing

The Lilly-Purdue partnership is making significant strides in pharmaceutical innovation and research, following its launch in May 2025.Since the announcement of a $250 million collaboration, Purdue University and Eli Lilly and Company have actively engaged in developing a shared research agenda aimed at enhancing drug discovery and manufacturing processes. This partnership, known as the Lilly-Purdue 360 Initiative, is notable for being the largest industry-academic agreement of its kind in the U
A stock certificate and financial report on a desk

May 8, 2026

Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares

Schrodinger Inc's recent financial performance has raised concerns among investors, as the company reported a larger-than-expected loss and fell short of revenue forecasts for Q1 2026, leading to a decline in its stock price.On May 7, 2026, Schrodinger's shares were trading at approximately $13.28 on Nasdaq. The company disclosed a net loss of around $60 million, or $0.81 per share, which is slightly worse than the previous year's loss of $59.8 million. This financial outcome has intensified scr
Minimalist illustration of an antibody and target

May 8, 2026

Europe's $154+ Million AI in Antibody Discovery Market,

The European market for AI in antibody discovery is poised for significant growth, projected to expand from approximately $153.8 million in 2025 to $1.43 billion by 2035, reflecting a compound annual growth rate (CAGR) of 25.05%.This growth is largely driven by the limitations of traditional antibody discovery methods, which are often costly and time-consuming. The integration of advanced technologies such as deep learning and generative AI is transforming the landscape, enabling more efficient
Close-up of human immune cells on a glass slide in a laboratory setting.

May 8, 2026

AstraZeneca Expands AI Biotech Partnership With Immunai Through 2027

AstraZeneca has strengthened its partnership with Immunai, focusing on AI-driven advancements in oncology and beyond. This collaboration, now extended through 2027, underscores the pharmaceutical giant's commitment to integrating cutting-edge technology into its drug development processes.The latest agreement allows Immunai to potentially earn up to $37.5 million as AstraZeneca leverages Immunai’s AMICA-OS platform, which utilizes AI to model the human immune system through extensive clinical da
Model of the human immune system in a research lab

May 7, 2026

AstraZeneca expands AI partnership with Immunai in deal worth up to $37.5 million

AstraZeneca is enhancing its collaboration with Immunai, focusing on artificial intelligence for oncology drug development. The expanded partnership could yield up to $37.5 million for Immunai through 2027, underscoring the increasing significance of AI technologies in pharmaceutical research.This collaboration builds on an existing relationship that began in 2024, with AstraZeneca utilizing Immunai's AMICA-OS platform. This AI-driven system models the human immune system, leveraging one of the
A minimalist illustration of a financial report with a rising chart

May 6, 2026

RVTY Q1 2026 Deep Dive: Portfolio Pruning and AI Investments Shape Outlook

Revvity's Q1 2026 results reveal a mixed performance with a focus on strategic adjustments and AI investments.Revvity (NYSE:RVTY) reported a 9.3% year-on-year revenue increase, totaling $686.9 million for Q1 CY2026, but fell short of market expectations, which were set at $705.1 million. Despite this, the company exceeded adjusted earnings per share (EPS) estimates, delivering $1.06 compared to the expected $1.01. The firm also adjusted its full-year revenue guidance downward to $2.83 billion fr
A minimalist illustration of a pill and a molecule in a dark palette.

May 6, 2026

AI in Drug Development: Where Value is Emerging

The integration of AI into drug development is reshaping the pharmaceutical landscape, promising faster and more cost-effective processes.The pharmaceutical sector is characterized by lengthy development timelines, substantial financial commitments, and high failure rates. AI emerges as a potential game-changer, aiming to streamline drug discovery and enhance success rates. However, the diverse nature of AI technologies and the extended timelines required for drug development make it challenging
A minimalist illustration of a test tube with bubbles, symbolizing drug discovery.

May 4, 2026

Big Tech Targets Drug Discovery with Wave of Life Science Platforms

Big tech companies are increasingly focusing on drug discovery, leveraging advanced AI and cloud platforms to streamline research and development processes.Nvidia's CEO, Jensen Huang, emphasizes that the future of accelerated computing lies in application acceleration rather than just hardware. This is particularly relevant in drug discovery, where lengthy approval processes and high clinical trial failure rates present significant challenges. To address these issues, major players like Amazon W
Silhouette of a human tonsil organoid

May 2, 2026

ALP Bio Raises €1.9M to Advance Immune Organoid AI Platform

ALP Bio AG has successfully raised €1.9 million in pre-seed funding to enhance its innovative immune organoid AI platform aimed at addressing immunogenicity risks in drug development.The funding round, led by Munich-based 42CAP with contributions from Venture Kick and angel investors, marks a significant step for the Swiss biotech startup founded in 2025. ALP Bio's platform uniquely integrates human tonsil organoid biology with generative AI to identify and mitigate the formation of anti-drug an
A minimalist representation of a drug compound in a dark palette.

May 2, 2026

OpenAI GPT-Rosalind: Specialized Life Sciences AI for Faster Drug Discovery Research

OpenAI has introduced GPT-Rosalind, a specialized AI model aimed at enhancing drug discovery efforts in the life sciences sector. This advanced tool is designed to assist researchers by leveraging deep scientific reasoning to navigate the complexities of biology and drug development, particularly within regulated environments.GPT-Rosalind operates under a controlled research preview, limiting access to qualified scientific users in regulated laboratory settings. Its primary focus is on translati
A minimalist illustration of a pill symbolizing drug discovery.

May 1, 2026

AI Tools Life Sciences Companies Are Using

Artificial Intelligence (AI) is increasingly embedded in the life sciences sector, influencing various stages from drug discovery to clinical research and manufacturing.The integration of AI tools in life sciences is transforming operations across the pharmaceutical value chain. Approximately 80% of professionals in this field utilize AI in drug discovery, with a significant majority of executives anticipating that intelligent automation will greatly impact the industry in the coming years. Comp